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 abstract
 context. Ghrelin is a hormone secreted primarily 
from stomach that can affect growth by its somatotropic and 
orexigenic activities. 
 objective. The aim of this study was to investigate 
the relationship of ghrelin and growth in children and 
adolescents with idiopathic short stature. 
 subjects and Methods. After thorough clinical 
examination, 56 subjects including 31 with normal weight 
and height and 25 with short stature were evaluated for 
fasting total (TG) and acylated (active) ghrelin (AG) levels. 
All the parameters of growth including growth hormone 
and IGF-1 levels, bone age and body mass index were also 
investigated. Appetite was also assessed and all the studied 
subjects were also divided into two groups, poor or good 
appetite. 
 results. TG and AG levels were not significantly 
different in the two groups. There was not any significant 
correlation between ghrelin and parameters of growth. On 
the other hand, TG concentration was significantly higher 
in subjects with poor appetite, but AG was not significantly 
different. 
 conclusions. The results of this study show that 
ghrelin is not significantly altered in idiopathic short stature. 
Although TG is increased in children with poor appetite its 
acylation is not increased concomitantly.
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inTroducTion
 Growth is one of the most distinctive 
characteristics of childhood. This process is the result 
of the interaction between multiple, diverse genetic, 
endocrine, and nutritional factors. Children normally 
grow at a predictable pattern; deviation from this pattern 
can be the first manifestation of an underlying problem 
which may be an endocrine or a nonendocrine disorder. 
Therefore, careful evaluation of growth is among the 
most important childcare issues (1). Many children 
who are referred to a paediatric endocrine clinic show 
deviations from the normal growth and the most frequent 
reason for referral to paediatric endocrinologist, after 
diabetes management, is for evaluation and treatment 
of short stature (2). Several biologic or physiologic 
problems are responsible for this situation and it is 
very important to assess and identify the underlying 
factors that may be associated with growth. There is 
often considerable overlap in the clinical presentation 
of patients given the diagnosis of “failure-to-thrive,” 
or “growth failure” with some patients presenting 
with poor linear growth, others with poor weight gain, 
and some with both (3). Underweight status has been 
associated with higher rates of morbidity and mortality, 
although to a lesser extent than obesity, and higher rates 
of asthma, scoliosis, intestinal problems and emotional 
disorders were found in underweight adolescents (4). 
 Ghrelin is a member of motilin family 
peptides. It consists of 28 amino acids, is mainly 
secreted from stomach and has various functions 
(1). Ghrelin is a natural growth hormone (GH) 
secretagogue that increases serum GH levels (5). It also 
has strong orexigenic properties and increases appetite. 
Nevertheless, ghrelin has been shown to exert many 
roles including regulation of glucose homeostasis, 
memory & learning, food addiction and neuroprotection 
(6). Ghrelin is acylated by the attachment of a medium-
chain fatty acid and circulates in two major forms, 
acylated and des-acylated ghrelin. This acylation is 
mandatory for its biologic effects on GH secretion and 
for binding at the receptor (5). 
 Total Ghrelin levels are decreased after 
consumption of a mixed meal and then are gradually 
increased (7). It seems that the orexigenic and metabolic 
properties of ghrelin are primarily mediated by its 
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action on the hypothalamus (8). Although studies with 
GH secretagogues, as well as the studies with ghrelin 
itself, have shown a significant and reproducible GH 
releasing effect (9), the physiological role of circulating 
ghrelin in the regulation of GH release is still not fully 
established (5). 
 Mutation in ghrelin receptor (GHSR) which 
impairs its constitutive activity, has shown to be 
associated with short stature (10) and GHSR-null mice 
have lower IGF-I levels when compared to wild type 
animals (11).
 Accordingly, it is possible that ghrelin can have 
potential impact on growth and it may play a major role 
in growth retardation whether short stature and/or low 
weight.
 The aim of this study was to investigate the total 
and acylated ghrelin levels in children with decline in 
growth in the form of short stature, low weight, or both 
and its relationship with growth parameters, serum 




 Fifty six subjects were selected from the 
children and adolescents who were referred to the 
endocrine clinic of Hazrat-e-Aliasghar Children 
Hospital. All of the children had a complete history 
and physical exam done by a single pediatrician. The 
subjects were also examined by a gastroenterologist 
and total serum IgA and anti-tissue transglutaminase 
antibody (anti-tTG) were measured to rule out Celiac 
or any other gastroenterological disease. In order 
to rule out any underlying disorder, erythrocyte 
sedimentation rate (ESR), complete blood count (CBC) 
with Differential, blood electrolytes, thyroid function 
tests, renal function tests, urinalysis, urine culture and 
stool exam were performed for all the subjects. 
 Fifty six children and adolescents were enrolled 
in his study. 
 Exclusion criteria were as follows: 1- any 
specific clinical conditions including genetic disorders 
(e.g., Prader–Willi syndrome), endocrinopathies, 
dysmorphic face, and mental illness; 2- history of 
chronic illness, trauma, major surgery, exposure to 
adverse conditions, inappropriate feeding practices or 
failure to thrive (FTT) in the past; 3- taking mediations; 
4- emotional disturbances; 5- gastrointestinal 
symptoms; 6- growth hormone or IGF-1 deficiency. 
 Inclusion criteria were as follows: 1- normal 
birth height and weight for gestational age; 2- suitable 
socioeconomic conditions. 3- age between 6 and 14 
years. 
 All the subjects were divided into two groups: 
short stature group (12 boys and 13 girls) and control 
group (11 boys and 20 girls). Inclusion criteria for short 
stature group was having distance from target height 
(DTH) less than -1.3 SDS (12). Apart from having 
short stature these children and adolescents were 
healthy and no cause for their short stature was found. 
DTH calculations are explained in the next section. 
Inclusion criteria for normal subjects were having DTH 
higher than -1.2 SDS and BMI between 5th and 90th 
percentiles. 
 Pubertal staging was determined by Tanner’s 
classification (13). 
 All the subjects or their parents gave informed 
consent, and subjects gave assent. The study conforms 
to the provisions of the Declaration of Helsinki in 1995 
(as revised in Tokyo 2004) and was approved by the 
ethics committee of Endocrinology and Metabolism 
Research Institute and Tehran University of Medical 
Sciences.
 Growth evaluation
 Height and weight were measured with an 
accuracy of 0.1 cm and 0.1 kg, respectively. Body mass 
index (BMI) was calculated as weight (kg) divided 
by the square of height (m). Height, weight and BMI 
percentiles for age and gender of each subject were 
obtained from US CDC growth charts and height SDS 
(HSDS), weight SDS (WSDS) and BMI SDS were 
calculated. Height of both parents was also recorded. 
Bone age was assessed by AP radiograph of left wrist 
according to Greulich and Pyle atlas (14). Bone age 
delay was calculated as bone age minus chronological 
age.
 Target height (TH) is one of the parameters 
of that is directly involved in growth monitoring. 
TH can be calculated based on the parents’ heights. 
Target height (TH) for boys and girls and their target 
height SDS (THSDS) were calculated with regard to 
their father’s (FH) and mother’s height (MH) by the 
following equations:
 TH (boys)= [(FH+MH)/2]+6.5.
 TH (girls)= [(FH+MH)/2]-6.5.
 THSDS= (TH-mean adult height for age and 
gender) / adult height SD.
 Distance from target height (DTH): HSDS - 
THSDS. 
 By comparing the HSDS of the child to its target 
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height, parental height and thus genetic factors are taken 
into account and those with familial short stature will 
be excluded (15). Those who had DTH less than -1.3 
SDS were considered as having idiopathic short stature, 
according to the Dutch consensus guidelines (12). 
 All the subjects were also evaluated for their 
BMI and those with BMI lower than 5th percentile for 
their age and gender were compared with those with 
normal BMI. 
 Appetite evaluation
 Appetite was evaluated based on Children’s 
Eating Behavior Questionnaire (CEBQ)(16). Three 
items evaluating food fussiness (e.g. my child is 
difficult to please with meal), three items evaluating 
satiety responsiveness (e.g. my child gets full up easily) 
were derived from CEBQ. The parents were also asked 
to categorize their children as having good and poor 
appetite. According to parents’ answers they were 
divided into good appetite and poor appetite categories. 
 Assays
 GH stimulation test was performed after 
administration of Clonidine for those children who were 
considered short stature. IGF-1 levels were measured 
for all subjects. Serum GH and IGF-1 were measured 
by chemiluminescence sandwich assay using directly 
coated magnetic microplates (Diasorin Ltd, UK). 
 For ghrelin measurement, blood was collected 
after an overnight fasting in tubes containing PMSF 
to the final concentration of 0.1 mg/mL as a protease 
inhibitor. The separated serum was acidified with HCl 
to a final concentration of 0.05 N and was frozen at 
-20°C for later use. Total ghrelin was measured by 
an Enzyme-linked immunosorbent assay (ELISA) kit 
(Millipore, UK), with intra- and inter-assay CV of 
5.58% and 6.24%, respectively. Acylated ghrelin was 
measured using a commercial ELISA kit (DRG, USA), 
with intra- and inter-assay CV of 6.3% and 5.4%, 
respectively. 
 Statistical analysis
 SPSS 16.0 was used for statistical analyses and 
data presentation. Shapiro-Wilk test was used to verify 
the normality of all continuous variables. Statistical 
comparisons between the groups were performed 
using t tests for normally distributed variables, 
Mann-Whitney U-tests for non-normally distributed 
variables and chi-square test for categorical variables. 
The Pearson and Spearman correlation analyses were 
used to evaluate the relationship among the various 
continuous variables. Results are expressed as the 
mean ± SD or median (interquartile range); p < 0.05 
was considered significant. 
resulTs
 In this study, 56 subjects were evaluated of 
which 25 (44%) were male and 31 (55%) were female. 
Characteristics of children with idiopathic short 
stature and control groups are summarized in Table 1. 
Chronological age was not significantly different 
between case and control groups whereas bone age 
delay was more prominent in subjects with poor growth 
compared to controls (p<0.01). GH and IGF-1 levels 
were within normal range for all the subjects, however, 
IGF-1 SDS was significantly lower in cases than that 
in controls. 
 Height SDS of cases was significantly lower 
than that in normal subjects (p<0.01). 
 There was no significant difference in fasting 
total ghrelin levels between the patients and normal 
Table 1. Characteristics of children with idiopathic retarded growth and normal children
Values are expressed as mean ± SD; †: Bone age delay = bone age – chronological age, ‡: data for total and acylated ghrelin is expressed as median 
(interquartile range); *: significant difference versus control group; HSDS: height SDS, THSDS: target height SDS; DTH: distance from target height (HSDS – 
THSDS).
control group iss p value
age (years) 8.70 ± 2.7 10.5 ± 3.4 0.54
Bone age (years) 7.80 ± 3.0 8.90 ± 3.9 0.46
Bone age delay (years)† -0.8 ± 1.1 -1.6 ± 1.1 0.01
hsds -0.64 ± 0.94 - 1.7 ± 0.55 0.00
Thsds -0.78 ± 0.6 -0.37 ± 0.55 0.01
dTh 0.13 ± 0.89 -1.6 ± 0.3 0.00
weight sds -0.39 ±0.6 - 0.94 ± 0.58 0.00
BMi sds -0.22 ± 0.7 -0.37 ± 0.75 0.44
iGF-1 (ng/ml) 171.5 ± 85.5 139.5 ± 85.04 0.09
iGF-1 sds 0.01 ± 0.57 - 0.4 ± 0.56 0.01
Total ghrelin (pg/ml)‡ 466.37 (281.1-748.7) 309.1 (212.9-713.8) 0.54
acylated ghrelin (pg/ml)‡ 90.1 (51.8-166.5) 86.0 (49.3-137.9) 0.21
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subjects, although ghrelin levels were slightly lower 
in patients than in normal subjects. Acylated ghrelin 
levels were not significantly different between patients 
and normal subjects but there was a trend towards 
lower acylated ghrelin levels in patients compared to 
normal children. 
 Although mean BMI SDS of case and control 
groups did not differ significantly, 48% of the subjects 
with idiopathic short stature had BMI lower than 5th 
percentile for their age and gender and therefore they 
were considered underweight. Total and acylated 
ghrelin levels were compared in underweight subjects 
and normal weight subjects and the values were not 
significantly different. 
 Total and acylated Ghrelin levels were not 
significantly different between male and female 
subjects, male and female patients or normal subjects, 
or prepubertal and pubertal stage. 
 All the subjects were divided into two groups 
based on their appetite. Sixty five percent of all the 
subjects had poor appetite, which comprised 53 % of 
normal subjects and 76% of patients. Poor eaters were 
characterized by lower food responsiveness, higher 
satiety responsiveness, and increased fussiness over 
food. The number of children with bad appetite was 
significantly higher in patient groups than in control 
group. BMI SDS was significantly lower in children 
with poor appetite (p<0.05). Total ghrelin levels were 
significantly higher in children with poor appetite than 
in children with good appetite (587.1 (285.1-906.0) 
vs. 381.4 (220.1-511.4) pg/mL, respectively; P < 0.05) 
(Fig. 1a). Comparing total ghrelin levels in normal 
subjects with good and poor appetite also showed 
significantly higher ghrelin levels in normal subjects 
with poor appetite than that in normal subjects with 
good appetite. On the other hand, acylated ghrelin 
levels were not significantly different in subjects with 
poor or appetite (92.3 (53.2-186.7) vs. 84.9 (44.1-
135.7) pg/mL, respectively).
 Neither acylated nor total ghrelin levels were 
significantly correlated with other variables. 
discussion
 The etiology of idiopathic short stature and 
poor growth is not well understood. 
 Ghrelin with its orexigenic and GH stimulating 
activities can be implicated in growth but whether its 
imbalance contributes to poor growth or not is still under 
debate. In the present study, no significant statistical 
difference was observed in total ghrelin as well as 
acylated or active ghrelin levels among children and 
adolescents with idiopathic short stature. However, the 
levels of this hormone were slightly lower in patients 
compared to healthy children although the difference 
was not significant. The relationship between ghrelin 
and growth in children has been studied previously 
but the results are not consistent and current data 
are insufficient to come to a conclusion about the 
involvement of ghrelin in growth retardation (3, 8, 17-
Figure 1. Median of (a) total and (b) acylated ghrelin levels in children and adolescents with good or poor appetite. Each box represents 25th and 
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19). This inconsistency may be due to the heterogeneous 
causes of suboptimal growth including genetic factors, 
GH-IGF axis abnormalities, malnutrition, and various 
endocrinopathies and environmental factors (8). The 
difference in total ghrelin levels in children with poor 
weight gain and suboptimal growth was significant in 
some studies (8, 18, 20) and not significant in others 
(19, 21, 22). 
 The relationship of acylated ghrelin and growth 
has been studied in two different studies. Tannenbaum 
et al. studied total and acylated ghrelin in 9 infants 
with FTT and 5 normal infants and showed that both 
acylated and total ghrelin were significantly elevated 
in FTT subjects compared with those observed in 
normally growing control infants. They proposed that 
increased ghrelin secretion in FTT infants is the result 
of an adaptive mechanism by their body attempting to 
increase appetite and preserve positive energy balance 
in response to poor nutritional status. Apart from FTT 
having a heterogeneous nature, their study consisted 
of mainly young infants and a small sample size. In 
comparison, in our study the age of the participants 
was higher and they did not have any history of FTT 
(23). Pinsker et al. also studied acylated ghrelin in 8 
patients with FTT (mean age 2.2 years), 33 patients 
with short stature (mean age 7.9 years) and 9 patients 
with isolated gastrointestinal symptoms (mean age 7.3 
years) which served as the control group. They found 
similar total ghrelin levels among different groups but 
higher acylated ghrelin levels in FTT patients versus 
those with isolated gastrointestinal symptoms and those 
with short stature. However, their study is different 
from the present study in that their normal subjects 
were not completely healthy, different groups were 
not age-matched, and various causes of short stature 
like rickets, renal tubular acidosis, growth hormone 
deficiency, and hypothyroidism were not ruled out (3). 
Thus the present study is the first one to investigate both 
acylated and total ghrelin levels in healthy children and 
adolescents with idiopathic short stature but without 
any present and past pathological conditions and any 
history of FTT. 
 It has been reported that weight loss as 
a consequence of consuming a low-calorie diet, 
increases ghrelin levels compared to a normal-
calorie diet and this effect has been attributed to a 
compensatory mechanism to increase food intake (24). 
This is a plausible explanation with regard to decreased 
postprandial ghrelin levels (19). But BMI SDS was not 
significantly correlated with ghrelin levels in our study. 
Pinsker et al. also showed in their study that total and 
acylated ghrelin levels were not significantly correlated 
with BMI z-scores (3). Therefore it seems that ghrelin 
is not changed in response to BMI SDS. 
 Nutrition plays a fundamental role in 
determining the growth of individuals and suboptimal 
nutrition can cause growth retardation and short stature 
(25). Any factor that interferes with appetite and 
eating behavior can directly or indirectly cause growth 
interruption and short stature (21). Many children 
with a history of poor appetite and being picky eaters 
have been shown to have a markedly lower body 
height (21). In this study it was shown that children 
with poor appetite had significantly higher total 
ghrelin concentrations than that in children with good 
appetite. However, acylated ghrelin levels were not 
significantly different between these two groups. Thus 
it seems that although ghrelin secretion is elevated as a 
compensatory mechanism, its acylation is not increased 
concomitantly. Therefore it cannot increase appetite in 
low weight children and this could indirectly affect 
their growth. Availability of medium-chain acyl-
molecules has been shown to affect ghrelin acylation 
(26). Poor nutrition may cause inadequacy of medium 
chain fatty acids for ghrelin acylation. Thus it seems 
possible that insufficient ghrelin acylation may be the 
cause of inefficient ghrelin function. 
 The relationship between total ghrelin and 
appetite has also been previously studied by Wudy et al. 
in normal children with good and poor appetite. They 
did not find any significant difference between the two 
groups, but mean BMI SDS of their whole sample was 
low (37th population percentile) and all of their subjects 
had below normal eating behavior. 
 in conclusion, the results of this study show 
that ghrelin levels are not significantly different 
between children and adolescents with poor growth 
and normal subjects. However, total ghrelin levels but 
not its acylated form is increased in children with poor 
appetite. Enhancing ghrelin acylation may be beneficial 
in increasing ghrelin orexigenic function in children 
and adolescents with poor appetite. 
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